With Eli Lilly’s Mounjaro entering India, the weight-loss drug race is on. But with steep prices and generics on the way, how ...

Mumbai-based Kilitch Drugs Ltd plans to enter biosimilars and oral solids, including diabetic and weight-loss tablets, and is ...

India's obesity crisis is intensifying, with big pharma companies like Eli Lilly and Novo Nordisk competing to introduce ...

Obesity remains a significant public health challenge in the UK, with over 26% of adults classified as obese and an additional 38% considered overweight. This epidemic not only impacts individual ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Eli Lilly on Thursday launched in India its diabetes and weight-loss drug, Mounjaro, which has already clocked in over $20 ...

While Indian pharmaceutical giants are already vying to capture the growing weight-loss drug market, small-cap firms are also eyeing a share of the pie, anticipating a post-patent-expiry boom as ...

The findings are particularly relevant as the T1D market continues to evolve. (Image Credits: Pexel) A new study has revealed that off-label use of semaglutide (Ozempic) and tirzepatide (Mounjaro ...

Next-gen weight-loss drugs like CagriSema and UBT251 could hit shelves within a year, promising more effective obesity and diabetes treatments.

The 2.5 mg vial and 5 mg vial will be available at Rs 3,500 and Rs 4,375, respectively. A spokesperson said as Mounjaro ...